We are live on
!
Find out more
Neurocrine Biosciences
NBIX
NBIX
126 hedge funds and large institutions have $759M invested in Neurocrine Biosciences in 2013 Q2 according to their latest regulatory filings, with 126 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
New
Increased
Maintained
Reduced
Closed
45% more call options, than puts
Call options by funds: $14.3M | Put options by funds: $9.91M
Holders
126
Holders Change
+126
Holders Change %
–
% of All Funds
4.11%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.07%
New
126
Increased
–
Reduced
–
Closed
–
Calls
$14.3M
Puts
$9.91M
Net Calls
+$4.43M
Net Calls Change
+$4.43M
Top Buyers
No buyers this quarter
Top Sellers
No sellers this quarter
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
US Bancorp
Minneapolis,
Minnesota
| $3K | +$2.46K | +200 | New |
|
NBIX Hedge Fund Activity: Q2 2013 in Review
126 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q2 2013, worth a combined $759M.
Buyers outnumbered sellers: 126 funds opened new NBIX positions and 0 closed out — a net gain of 126 holders — while 0 added to existing stakes and 0 trimmed.
- 126 institutional investors held Neurocrine Biosciences (NBIX) as of Q2 2013, up from 0 in Q1 2013.
- Funds reported $759M of Neurocrine Biosciences stock for Q2 2013.
- 126 funds opened new Neurocrine Biosciences positions in Q2 2013 and 0 closed out, a net change of +126 holders.
Based on aggregated 13F filings for Q2 2013.